 | Up a level |
Rüeger, S; Bochud, P-Y; Dufour, Jean-François; Müllhaupt, B; Semela, D; Heim, M H; Moradpour, D; Cerny, A; Malinverni, R; Booth, D R; Suppiah, V; George, J; Argiro, L; Halfon, P; Bourlière, M; Talal, A H; Jacobson, I M; Patin, E; Nalpas, B; Poynard, T; ... (2014). Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut, 64(10), pp. 1605-1615. BMJ Publishing Group 10.1136/gutjnl-2014-306997
Bochud, PY; Bibert, S; Kutalik, Z; Patin, E; Guergnon, J; Nalpas, B; Goossens, N; Kuske, L; Müllhaup, B; Gerlach, T; Heim, MH; Moradpour, D; Cerny, A; Malinverni, R; Regenass, S; Dollenmaier, G; Hirsch, H; Martinetti, G; Gorgiewski, M; Boulière, M; ... (2011). Swiss Hepatitis C Cohort Study Grp. IL28B Polymorphisms Linked to Poor Response To Treatment are Associated with Low Necroinflammatory Activity and Slow Fibrosis Progression in HCV Genotype Non-1-Infected patientsBern. Hepatology, 54(1), p. 539. Hoboken, N.J.: Wiley Interscience 10.1016/S0168-8278(11)61363-9
Puoti, M; Foster, G; Wang, S; Mutimer, D; Gane, E; Moreno, C; Tsung Chang, T; Lee, SS; Marinho, R; Dufour, Jean-François; Pol, S; Hezode, C; Gordon, SC; Strasser, SI; Thuluvath, PJ; Liu, R; Pilot-Matias, T; Mensa, F (14 September 2017). High SVR Rates with 8 and 12 Weeks of Pangenotypic GlecapreviriPibrentasvir: PH2 Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis. Swiss medical weekly, 147(Suppl 225), p. 20. EMH Schweizerischer Ärzteverlag
